Keywords: kos, co-promote, knoll, antihypertensives, pharmaceuticals, signed, agreement
Kos to co-promote Knoll's antihypertensives
Article | 29 July 1999
Kos Pharmaceuticals has signed an agreement with KnollPharmaceutical to co-promote the latter's antihypertensive compounds Mavik (trandolapril) and Tarka (trandolapril/extended-release ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
